Axelyf
Axelyf identifies AX-004 as its proprietary in vivo CAR-T candidate for solid tumors using AXL LNP delivery. Disclosed support is from mouse and non-human-primate studies; human dosing or clinical efficacy is not inferred.
Corporate information
- Company entity
- Axelyf
- Headquarters / principal office
- Brookline, MASelf-reported location on the company LinkedIn page; regional scope may differ from the legal or global headquarters. ↗
- Founded
- 2022 ↗
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- https://www.axelyf.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Axelyf identifies AX-004 as its proprietary in vivo CAR-T candidate for solid tumors using AXL LNP delivery. Disclosed support is from mouse and non-human-primate studies; human dosing or clinical efficacy is not inferred.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Axelyf proprietary AX-004 and AX-003 programs
- Axelyf — primary program / ownership disclosure
- Axelyf — official About page
- Company-managed LinkedIn profile — self-reported location